Related Experiment Video

Updated: Sep 5, 2025

Osmotic Minipump Implantation for Increasing Glucose Concentration in Mouse Cerebrospinal Fluid
06:21

Osmotic Minipump Implantation for Increasing Glucose Concentration in Mouse Cerebrospinal Fluid

Published on: April 7, 2023

1.6K

Effect of Chronic Heart Failure Complicated with Type 2 Diabetes Mellitus on Cognitive Function in the Elderly

Yang Liu1, Rui Meng2, Jianzeng Dong1

  • 1Department of Cardiology, Anzhen Hospital, Capital Medical University, Beijing 100029, China.

Evidence-Based Complementary and Alternative Medicine : Ecam
|July 8, 2022
PubMed

Insights

Elderly patients with chronic heart failure and type 2 diabetes mellitus experience worsened cognitive function. Type 2 diabetes is a key risk factor, accelerating cognitive decline and impairing executive abilities.

Area of Science:

  • Gerontology
  • Cardiology
  • Endocrinology

Background:

  • Chronic heart failure (CHF) and type 2 diabetes mellitus (T2DM) are prevalent in the elderly.
  • Cognitive impairment is a significant concern in this demographic.

Purpose of the Study:

  • To investigate the impact of T2DM on cognitive function in elderly patients with CHF.
  • To identify T2DM as a risk factor for cognitive decline in CHF patients.

Main Methods:

  • A cohort of 600 elderly patients with CHF was divided into two groups: CHF with T2DM (Group A) and CHF alone (Group B).
  • Cognitive function was assessed using Mini-Mental State Examination (MMSE) and Montreal Cognitive Assessment (MoCA) scores.
  • Cardiac function (LVEF) and anxiety/depression scores (HAMA, HAMD) were also evaluated.

Main Results:

  • Group A (CHF with T2DM) exhibited significantly lower baseline MMSE and MoCA scores compared to Group B.
  • While both groups showed cognitive improvement post-intervention, Group B demonstrated a significantly greater increase in MMSE and MoCA scores.
  • Multivariate analysis identified fasting blood glucose and glycosylated hemoglobin as significant risk factors for cognitive impairment.

Conclusions:

  • T2DM exacerbates cognitive impairment in elderly patients with CHF.
  • T2DM is an independent risk factor that accelerates cognitive decline and impairs executive function in this population.
Abstract

More Related Videos

Modeling and Evaluation of Murine Diabetic Cardiomyopathy Model06:22

Modeling and Evaluation of Murine Diabetic Cardiomyopathy Model

Published on: November 29, 2024

753
Evaluation of the Cognitive Performance of Hypertensive Patients with Silent Cerebrovascular Lesions07:30

Evaluation of the Cognitive Performance of Hypertensive Patients with Silent Cerebrovascular Lesions

Published on: April 23, 2021

3.1K

Related Concept Videos

Heart Failure II: Pathophysiology01:29

Heart Failure II: Pathophysiology

Systolic Heart Failure and Compensatory MechanismsSystolic heart failure (also termed HFrEF, Heart Failure with Reduced Ejection Fraction) is the most prevalent type of heart filure. It results in a decreased volume of blood being pumped from the ventricle. The aortic arch and carotid sinuses have baroreceptors that detect reduced blood pressure, triggering the sympathetic nervous system (SNS) to release epinephrine and norepinephrine. Initially, this response aims to boost heart rate and...
31
Psychoneuroimmunology: Diabetes and Cancer01:19

Psychoneuroimmunology: Diabetes and Cancer

Chronic stress has been linked to both the onset and progression of serious health conditions, including Type 2 diabetes and cancer. Type 2 diabetes, a widespread chronic illness, is closely associated with obesity and insulin resistance, both of which often worsen under stress. Studies indicate that men experiencing high levels of chronic stress face a 45% higher risk of developing diabetes compared to those with minimal stress. Stress triggers physiological responses that elevate blood...
61
Heart Failure I: Introduction01:27

Heart Failure I: Introduction

Heart failure refers to a clinical syndrome caused by structural or functional cardiac disorders that prevent the heart from pumping an adequate amount of blood to meet the body's metabolic needs. This condition often arises from myocardial infarction or ischemia, leading to decreased cardiac output, reduced tissue perfusion, impaired gas exchange, fluid volume imbalance, and decreased functional ability.Heart failure can result from disruptions in the mechanisms that regulate cardiac output...
46
Heart Failure IV: Classification and Diagnostic Evaluation01:30

Heart Failure IV: Classification and Diagnostic Evaluation

Heart failure can be classified in various ways, with the most common classifications based on physical activity limitations, disease progression, severity, and treatment strategies.The Functional Classification of Heart Failure divides patients into four categories based on physical activity limitation due to symptom burden.Class I: Patients in this class have cardiac disease but no physical activity limitations. Ordinary activities like walking, climbing stairs, or routine tasks do not cause...
27
Heart Failure III: Clinical Manifestations01:26

Heart Failure III: Clinical Manifestations

Heart failure (HF) manifests primarily as dyspnea, fatigue, and fluid retention, resulting in peripheral and pulmonary edema. Symptoms may vary depending on which ventricle is more affected, left or right.Left-Sided Heart FailureAlso known as left ventricular failure, this condition results from the left ventricle's inability to fill or eject sufficient blood into the systemic circulation. It leads to pulmonary congestion, which occurs when the left ventricle fails to eject blood effectively...
41
Heart Failure Drugs: Inhibitors of Renin-Angiotensin System01:26

Heart Failure Drugs: Inhibitors of Renin-Angiotensin System

The activation of the sympathetic nervous system and the renin-angiotensin-aldosterone system (RAAS) contributes to cardiac remodeling, and inhibiting the RAAS is a pharmacological target in heart failure management. As a result, neurohumoral modulation is a crucial treatment principle for managing heart failure. This approach involves using medications like ACE inhibitors (ACEIs), angiotensin receptor blockers (ARBs), β-blockers, mineralocorticoid receptor antagonists (MRAs), and neutral...
503